US9346745B2 - Process for producing Aliskiren - Google Patents

Process for producing Aliskiren Download PDF

Info

Publication number
US9346745B2
US9346745B2 US13/701,440 US201113701440A US9346745B2 US 9346745 B2 US9346745 B2 US 9346745B2 US 201113701440 A US201113701440 A US 201113701440A US 9346745 B2 US9346745 B2 US 9346745B2
Authority
US
United States
Prior art keywords
compound
formula
reaction
vii
process according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related, expires
Application number
US13/701,440
Other languages
English (en)
Other versions
US20130071899A1 (en
Inventor
Maurizio TADDEI
Adele Russo
Elena Cini
Renata Riva
Marcello Rasparini
Luca Carcone
Luca Banfi
Romina Vitale
Stephen Roseblade
Antonio Carlo Zanotti-Gerosa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemo Iberica SA
Original Assignee
Chemo Iberica SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ITMI2010A001008A external-priority patent/IT1400961B1/it
Priority claimed from ITMI2010A002271A external-priority patent/IT1402925B1/it
Application filed by Chemo Iberica SA filed Critical Chemo Iberica SA
Assigned to CHEMO IBERICA, S.A. reassignment CHEMO IBERICA, S.A. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: Carcone, Luca, RASPARINI, MARCELLO, RUSSO, ADELE, BANFI, LUCA, RIVA, RENATA, VITALE, ROMINA, CINI, ELENA, TADDEI, MAURIZIO, ROSEBLADE, STEPHEN, ZANOTTI-GEROSA, ANTONIO CARLO
Publication of US20130071899A1 publication Critical patent/US20130071899A1/en
Application granted granted Critical
Publication of US9346745B2 publication Critical patent/US9346745B2/en
Expired - Fee Related legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/14—Preparation of carboxylic acid amides by formation of carboxamide groups together with reactions not involving the carboxamide groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/16—Preparation of optical isomers
    • C07C231/18—Preparation of optical isomers by stereospecific synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/02—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups from isocyanates with formation of carbamate groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/303—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by hydrogenation of unsaturated carbon-to-carbon bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/333—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton
    • C07C67/343—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/02—Amides, e.g. chloramphenicol or polyamides; Imides or polyimides; Urethanes, i.e. compounds comprising N-C=O structural element or polyurethanes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
    • C12P41/002—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by oxidation/reduction reactions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
    • C12P41/003—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions
    • C12P41/005—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions by esterification of carboxylic acid groups in the enantiomers or the inverse reaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/24—Preparation of oxygen-containing organic compounds containing a carbonyl group
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01001—Carboxylesterase (3.1.1.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/52—Improvements relating to the production of bulk chemicals using catalysts, e.g. selective catalysts

Definitions

  • the present invention relates to a process for producing Aliskiren.
  • Aliskiren is the compound having the IUPAC name (2S,4S,5S,7S)—N-(2-carbamoyl-2-methylpropyl)-5-amino-4-hydroxy-2,7-diisopropyl-8-[4-methoxy-3-(3-methoxypropoxy)phenyl]-octanamide and the following structure (I):
  • This compound is the first molecule known to be capable of directly inhibiting the functionality of renin, an enzyme involved in the processes of regulation of blood pressure, and is used in the treatment of hypertension.
  • Patent EP 1,303,478 B1 teaches a route of synthesis of Aliskiren currently used for its industrial production.
  • synthesis described in this document firstly it requires the use of Grignard reagents, which are known to be difficult to use on an industrial scale, owing to the highly exothermic nature of the reactions in which they take part; secondly, this synthesis requires the use of aluminium diethyl chloride, a pyrophoric and corrosive reagent, requiring the use of specialized equipment.
  • the aim of the present invention is to provide a novel process for producing Aliskiren that allows the disadvantages of the prior art to be overcome, as well as to provide a novel compound that can be used in the process.
  • R is selected from hydrogen, alkyl or substituted alkyl, aryl or substituted aryl; and Y is selected from: a group —OR 1 , in which R 1 has the same meanings defined above for R; the radical (S)-4-benzyloxazolidin-2-on-3-yl; or the radical 2-carbamoyl-2-methylpropylamine, of formula:
  • Compound (V) can be prepared (operation A of the process of the invention) according to two alternative routes of synthesis A.i) and A.ii).
  • reaction pathway A.ii) comprises reaction of the derivative of (R)-2-[4-methoxy-3-(3-methoxypropoxy)benzyl]-3-methyl-butyl of formula (II′), in which X represents a leaving group, with the beta-ketoester of formula (III) to form product (V):
  • Operation B of the process of the invention transformation of a compound of formula (V) into an intermediate of formula (VII), can be carried out according to three possible alternative reaction pathways, designated hereunder as B.i), B.ii) and B.iii).
  • Reaction pathway B.i comprises:
  • reaction pathway B.iii) comprises direct asymmetric hydrogenation of compound (V) to compound (VII).
  • reaction pathway C.i The transformation of intermediate (VII) into the cyclic carbamate (VIII) takes place according to the reaction pathway C.i), which can be represented schematically as follows:
  • the reactions for transforming compound (VII) into compound (VII′) are the typical reactions of hydrolysis or deprotection of esters of carboxylic acids, i.e. basic or acid hydrolysis or hydrogenolysis in the case when the group R is benzyl. These conditions are also suitable in most cases for deprotection of the alcohol function if P is an acyl group, such as acetyl, or a carbamoyl group. In the case when P is a trimethylsilyl group the hydrolytic conditions are sufficient for its removal.
  • P is a sterically hindered silyl group such as tert-butyldimethylsilyl (TBDMS) or tert-butyldiphenylsilyl (TBDPS) action of the fluoride ion or of hydrogen fluoride is more appropriate.
  • TDMS tert-butyldimethylsilyl
  • TDPS tert-butyldiphenylsilyl
  • the first route, C.ii) envisages the following reactions:
  • the first part of the synthesis comprises formation of the compound of formula (V) according to two possible alternative routes of synthesis, indicated above as A.i) and A.ii), which have in common the use of the compounds of general formula (III), homochiral isopropyl-substituted beta-ketoesters; these compounds are novel and constitute a second aspect of the invention.
  • R 6 is an alkyl or haloalkyl group, for example methyl, ethyl, propyl, butyl or 2,2,2-trifluoroethyl.
  • the preparation of compounds of type (X) is known from patent EP 1,296,912 B1.
  • Compound (X) can easily be dehydrated with acid catalysis by removal of the —OH group in the benzylic position, owing to the stability of the double bond conjugated with the phenyl that is derived from it; it is possible for example to work in toluene or in xylene under reflux, using a strong organic or mineral acid such as camphorsulphonic or para-toluenesulphonic acid or sulphuric acid; the result of dehydration is compound (XI):
  • ester group of compound (XII) is then hydrolysed enzymatically to supply the corresponding acid.
  • the chiral centre in the a position relative to the carboxyl carbon is produced selectively, obtaining (R)-2-[4-methoxy-3-(3-methoxypropoxy)benzyl]-3-methyl-butanoic acid of formula (XIII):
  • compound (XIII) is produced starting from compound (XII) by enzymatic hydrolysis.
  • animal liver extracts are used, in particular “Pig Liver Esterase” (PLE); or animal liver powders dehydrated with acetone (generally known in this field as “liver acetone powder”), such as “sheep liver acetone powder” (SLAP), “bovine liver acetone powder” (BLAP) and, preferred for the purposes of the invention, “horse liver acetone powder” (HLAP).
  • Enzymatic hydrolysis is performed with a substrate that is preferably a compound of formula (XII) in which R is n-butyl, at a concentration between 10 and 1000 mM, and preferably between about 90 and 100 mM; at a temperature between room temperature and about 50° C., and preferably of about 40° C.; and in a buffered water-based solvent at a pH between about 5 and 9, for example a phosphate-based buffer, or preferably in a tris(hydroxymethyl)aminomethane/HCl buffer system maintained at a pH of about 7.5; it is also possible to work in the presence of a co-solvent, selected for example from methanol (MeOH), ethanol (EtOH), tert-butanol (t-BuOH), tetrahydrofuran (THF), dimethylformamide (DMF), acetone, acetonitrile, di-isopropyl ether (i-Pr 2 O) and dimethylsulphoxide (DM
  • the enzymatic transformation from compound (XII) to compound (XIII) according to the invention has some advantages relative to the corresponding reactions given in documents EP 1,296,912 B1 and WO 02/02500 A1 cited above.
  • the reaction takes place in mild conditions (for example, pH 7.5 and at 40° C.), with good conversion yield (about 40% against a theoretical 50%) and with enantiomeric excesses of about 96-97%, comparable or better than those obtainable with enantioselective hydrogenations; moreover, the unhydrolysed ester can easily be recovered and racemized, for reuse in the same reaction, thus increasing the overall yield of the desired product.
  • the alcohol (XIV) can then be submitted to controlled oxidation to supply the aldehyde (II), the reagent of A.i.1); or can be halogenated or activated to supply a compound of formula (II′), the reagent of A.ii.1).
  • the leaving group is a halogen
  • said compound can be obtained by reacting an alkaline halide such as sodium or potassium bromide or iodide with the activated derivative, for example by reacting the mesylate or tosylate with sodium iodide in an aprotic dipolar solvent such as dimethylformamide or dimethylacetamide or acetonitrile or methyl ethyl ketone.
  • an alkaline halide such as sodium or potassium bromide or iodide
  • an aprotic dipolar solvent such as dimethylformamide or dimethylacetamide or acetonitrile or methyl ethyl ketone.
  • Halogenation can also be performed directly on alcohol (XIV) by reaction for example with bromine or iodine in the presence of a stoichiometric amount of a phosphine such as triphenyl phosphine and an organic base such as triethylamine or imidazole.
  • a phosphine such as triphenyl phosphine
  • an organic base such as triethylamine or imidazole.
  • the iodo-derivative is particularly useful for the purposes of synthesis of Aliskiren.
  • the leaving group can be a sulphonate such as methanesulphonate (mesylate), trifluoromethanesulphonate (triflate) or, preferably, paratoluenesulphonate (tosylate); these derivatives are prepared starting from alcohols (such as the compound of formula (XIV)) by techniques that are well known.
  • compound (III), used in reactions A.i.1) or A.ii.1) can be prepared as described below.
  • the first step in the preparation comprises reaction between 3-methylbutanoyl chloride and an Evans homochiral oxazolidinone (chiral auxiliary), in particular the oxazolidinone derived from (S)-phenylalaninol in an inert solvent such as dichloromethane or more conveniently acetonitrile in the presence of an inorganic base such as an alkaline carbonate or an organic base such as a tertiary amine, for example triethylamine optionally in the presence of a catalyst of the acylation reaction such as 4-dimethylaminopyridine (DMAP), at a temperature between 0 and 5° C., with formation of an intermediate of type (XV):
  • an Evans homochiral oxazolidinone derived from (S)-phenylalaninol in an inert solvent such as dichloromethane or more conveniently acetonitrile in the presence of an inorganic base such as an alkaline carbonate or an organic base such as a
  • the intermediate (XV) is treated, in an aprotic solvent (preferably THF) and at low temperature (for example, ⁇ 40° C.), with a strong base, for example lithium diisopropylamide (LDA) or lithium, sodium or potassium bis(trimethylsilyl)amide (LiHMDS, NaHMDS or KHMDS); next, an ⁇ -halide of an ester of acetic acid, of general formula X—CH 2 —COOZ, in which Z can be for example benzyl or tert-butyl, is added to the solution, forming the intermediate (XVI):
  • a strong base for example lithium diisopropylamide (LDA) or lithium, sodium or potassium bis(trimethylsilyl)amide (LiHMDS, NaHMDS or KHMDS)
  • LDA lithium diisopropylamide
  • LiHMDS, NaHMDS or KHMDS lithium, sodium or potassium bis(trimethylsilyl)amide
  • Deprotection can take place by hydrogenolysis, for example with gaseous hydrogen in the presence of a catalyst based on transition metals supported on an inert matrix, for example palladium on carbon, in the case when Z is benzyl, or by means of strong acids, such as formic, hydrochloric or trifluoroacetic acid, in the case when Z is tert-butyl.
  • a catalyst based on transition metals supported on an inert matrix for example palladium on carbon
  • strong acids such as formic, hydrochloric or trifluoroacetic acid
  • the intermediate (XVI′) is finally activated first with carbonyl diimidazole, and then reacted with a magnesium salt of a monoester of malonic acid of general formula (R 1 OC(O)—CH 2 —COO ⁇ ).1 ⁇ 2Mg 2+ , in which R 1 is a C 1 -C 6 alkyl or benzyl according to the Masamune homologation reaction; the result of the reaction is the desired compound (III).
  • the chiral auxiliary in the intermediate (XVI) can be replaced with a benzyloxy group by reaction with the lithium salt of benzyl alcohol.
  • the benzyl group thus introduced can be removed by hydrogenolysis and the acid obtained can be converted into the ester of interest, for example methyl, ethyl, isopropyl, tert-butyl, cyclohexyl ester.
  • the synthesis scheme of compound (III) can be summarized as follows:
  • R′ and R′′ can be alkyl or benzyl.
  • Compound (V) can be obtained by hydrogenation of the C ⁇ C double bond of compound (IV). Hydrogenation is carried out using palladium on carbon or on another inert matrix such as silica or alumina, preferably carbon, as catalysts. It is also possible to use palladium hydroxide supported on carbon, platinum on carbon or platinum oxide, preferably platinum oxide or Raney nickel.
  • the hydrogenation reaction is carried out in an inert solvent such as tetrahydrofuran or ethyl acetate, preferably in tetrahydrofuran, with hydrogen at ambient pressure or at a pressure between 1 and 10 bar, preferably at ambient pressure.
  • an inert solvent such as tetrahydrofuran or ethyl acetate, preferably in tetrahydrofuran, with hydrogen at ambient pressure or at a pressure between 1 and 10 bar, preferably at ambient pressure.
  • Compound (IV) is obtained by Knoevenagel reaction of the aldehyde (II) and of the beta-ketoester (III), dissolving both reactants in a polar aprotic solvent such as dimethylacetamide or dimethylformamide or in an apolar aprotic solvent such as toluene and using piperidine, morpholine or pyridine as catalyst, preferably piperidine optionally together with an equal stoichiometric amount of an organic acid such as acetic acid or benzoic acid.
  • the reaction can be carried out at a temperature between about 20 and 50° C., preferably about 25° C.
  • the reaction between (II) and (III) can also be carried out using the Lehnert modification of the Knoevenagel reaction, i.e. using a stoichiometric amount of titanium tetrachloride and of pyridine in an inert solvent such as dichloromethane at a temperature between ⁇ 20 and 20° C., preferably at 0° C.
  • Compound (V) can also be obtained directly by C-alkylation of the beta-ketoester (III) with an activated derivative (II′).
  • the reaction takes place in a polar aprotic solvent such as dimethylformamide, dimethylacetamide, tetrahydrofuran or preferably acetonitrile, or in a polar protic solvent such as tert-butanol, in the presence of a base;
  • the base can be inorganic, such as a carbonate of an alkali metal or alkaline-earth metal such as sodium carbonate, potassium carbonate, caesium carbonate or calcium carbonate, preferably sodium or potassium carbonate; or an organic base, such as an alcoholate of lithium, of sodium or of potassium, preferably tert-butylate of sodium or of potassium.
  • the reaction can be carried out at temperatures between about 20° C. and the reflux temperature of the solvent, preferably between 40° C. and 60° C.
  • the compound of formula (V) is converted to the enol ether (VI) by treatment of (V) with an acylating agent such as acetic anhydride or a silylating agent such as trimethylsilyl chloride, and an organic or inorganic base, preferably a tertiary amine, optionally in an inert solvent such as dichloromethane or toluene.
  • an acylating agent such as acetic anhydride or a silylating agent such as trimethylsilyl chloride
  • an organic or inorganic base preferably a tertiary amine, optionally in an inert solvent such as dichloromethane or toluene.
  • the stereoselective hydrogenation of an enol derivative of formula (VI) to give a compound of formula (VII) is carried out using a catalyst based on a transition metal such as ruthenium, rhodium, iridium, nickel, palladium, platinum or salts thereof, optionally mixed, and optionally supported on an inert matrix such as carbon, silica or alumina or on an organic polymer matrix.
  • a transition metal such as ruthenium, rhodium, iridium, nickel, palladium, platinum or salts thereof, optionally mixed, and optionally supported on an inert matrix such as carbon, silica or alumina or on an organic polymer matrix.
  • the transition metal is used in the form of a complex that is soluble in the reaction medium optionally coordinated with an achiral or chiral mono- or bidentate phosphine.
  • chiral phosphines these can be used as a racemic mixture, in enantiomerically enriched form or in the form of a single enantiomer.
  • Homogeneous catalysts of rhodium or ruthenium or iridium coordinated with bidentate phosphines such as TCFP, PhanePhos, Binap, DiPFc, BoPhoz and DCPF are particularly preferred.
  • R hydrogen
  • a salt of the compound in particular its salts of alkali metals or alkaline earth metals or of amines, preferably tertiary alkyl amines such as triethylamine.
  • a salt of the compound in particular its salts of alkali metals or alkaline earth metals or of amines, preferably tertiary alkyl amines such as triethylamine.
  • a salt of the compound in particular its salts of alkali metals or alkaline earth metals or of amines, preferably tertiary alkyl amines such as triethylamine.
  • the optimum conditions for the reaction of hydrogenation of an enol derivative of formula (VI) envisage the use of a catalyst of rhodium (I), which can be achiral, such as [Rh(DiPFc)(cod)]BF 4 , or preferably chiral, such as [((S)-PhanePhos)Rh(cod)]BF 4 ; or catalysts of ruthenium (II) such as [Ru(R-Binap)(benzene)Cl]Cl in halogenated solvents such as 1,2-dichloroethane or, preferably, dichloromethane, or alcohols such as methanol, isopropanol, or preferably ethanol, at a temperature between 40 and 80° C., preferably about 60° C., at a hydrogen pressure between 5 and 30 bar, preferably about 30 bar.
  • a catalyst of rhodium (I) which can be achiral, such as [Rh(DiPFc)(cod
  • the reaction is preferably carried out in the presence of an aliphatic tertiary amine such as ethyl-diisopropylamine or, preferably, triethylamine, in a molar ratio between 0.5 and 1 (preferably 0.7) with the enol derivative of formula (VI).
  • the formation of the salt with the tertiary amine can take place directly in the reaction medium.
  • the molar ratio of catalyst to substrate is from 1/10000 to 1/100, preferably 1/1000.
  • This technology provides controlled formation of two stereocentres when the beta-ketoester has a labile stereocentre in the alpha position by a process of dynamic kinetic resolution.
  • a cofactor such as NAD for example and optionally in the presence of a system able to regenerate the cofactor.
  • the carbamate (VII′′′′) is then submitted to acid hydrolysis to detach the protecting group P on the alcohol function and to hydrolyse group Y: the hydroxy acid thus obtained undergoes cyclization spontaneously to give the lactone (IX′′).
  • Suitable conditions for acid hydrolysis are strong mineral or organic acids, if desired in aqueous solution, such as hydrochloric or sulphuric or formic or para-toluenesulphonic acid mixed with water-miscible alcoholic solvents such as methanol, ethanol, isopropanol. It is also possible to use acid resins such as Dowex or Nafion.
  • the reaction of acid hydrolysis and cyclization is carried out at a temperature between 50° C. and the reflux temperature of the solvent.
  • a 250-ml jacketed reactor is charged, under nitrogen atmosphere, with 86.1 ml of a 0.72 M solution of lithium diisopropylamide in THF, heptane and ethylbenzene, equal to 62.0 mmol of the base.
  • the solution is cooled to ⁇ 40° C., and 15 ml of a solution of butyl isovalerate in anhydrous THF, containing 8.16 g (51.5 mmol) of the ester, are added slowly, in 30 minutes.
  • Compound (X) is submitted to catalytic hydrogenation in methanol (120 ml) with Pd/C at 10% (1 mol. %) at room temperature, working with ambient pressure of hydrogen; this operation takes 18 hours.
  • a 100-ml flask equipped with an efficient magnetic stirrer is charged with 1.134 g of methyl-2-(4-methoxy-3-(3-methoxypropoxy)benzyl)-3-methylbutanoate (3.5 mmol) obtained by saponification and esterification with methanol of the butyl ester obtained in the preceding example; then 85 ml of a 0.3 M buffer solution of tris(hydroxymethyl)aminomethane/HCl with pH 7.5 are added. The mixture is stirred at high speed producing a finely dispersed suspension.
  • the filtrate is transferred to a reparatory funnel, the phases are separated and the aqueous phase is re-extracted with ethyl ether.
  • the degree of conversion (evaluated with 1 H NMR) is equal to 50.6%.
  • the enantioselectivity, E, of the mixture is also measured, and is found to be 40.3.
  • a 25-ml flask equipped with a magnetic stirrer is charged with 309 mg (1.043 mmol) of compound (XIV) of the preceding example, 5 ml of dichloromethane, 5 ml of an aqueous solution of concentration 0.5 M of NaHCO 3 and 0.05 M of K 2 CO 3 , 16.3 mg (0.1043 mmol) of TEMPO free radical and 29 mg of tetrabutylammonium chloride (0.1043 mmol).
  • the two-phase mixture is stirred at the maximum speed of the magnetic stirrer and 200 mg (1.49 mmol) of N-chlorosuccinimide are added in a single portion.
  • the mixture is diluted with 20 ml of dichloromethane and 20 ml of water, the phases are separated and the organic phase is washed with 10 ml of brine, dried over sodium sulphate and concentrated to constant residue, obtaining 279 mg of product as dense yellow oil (yield 91%).
  • the mesylate is taken up in acetonitrile (20 ml) and sodium iodide is added (4.50 g, 30 mmol) and it is heated under reflux under nitrogen overnight. Then the solvent is evaporated and it is taken up in toluene (25 ml) and is washed twice with water (2 ⁇ 10 ml), then it is dried over sodium sulphate and is evaporated to dryness obtaining the product in the form of a white solid (4.05 g, 94% yield) that does not require further purification.
  • tert-butylbromoacetate (10.7 ml, 72.7 mmol) is added. The temperature is raised to 20° C. in 4 hours, then a saturated solution of ammonium chloride (50 ml) is added, the tetrahydrofuran is evaporated and the suspension thus obtained is extracted twice with ethyl acetate (2 ⁇ 100 ml). The combined organic phases are washed with 0.5N HCl, brine and are dried over sodium sulphate.
  • the product is obtained as in the procedure described in the preceding example and using benzyl bromoacetate instead of tert-butylbromoacetate.
  • the product is obtained by crystallization from isopropanol (yield 72%) as a white solid, m.p. 104° C.
  • the trifluoroacetic acid is distilled at ambient pressure with the purpose of recovering it, the last traces of acid are removed under vacuum and the residue is taken up in toluene (100 ml) and saturated aqueous solution of NaHCO 3 (600 ml); the desired product is extracted in the aqueous phase.
  • the aqueous phase is washed with toluene (100 ml) and the product is extracted in toluene after adjusting the pH to 2 with 1M H 2 SO 4 .
  • the toluene is concentrated to residue, then it is taken up in methyl tert-butyl ether (200 ml) and cyclohexylamine is added until there is quantitative precipitation of the product and it is filtered.
  • the product is washed with methyl tert-butyl ether and is dried under vacuum at 25° C.
  • the product is obtained by a procedure similar to that described in example 10 using (S)-3-(benzyloxycarbonyl)-4-methylpentanoic acid instead of (S)-3-((S)-4-benzyloxazolidin-2-on-3-yl)-carbonyl-4-methyl pentanoic acid. Yield isolated after flash chromatography 72%.
  • the product is obtained by a procedure similar to that described in example 10 using (S)-3-(benzyloxycarbonyl)-4-methylpentanoic acid instead of (S)-3-((S)-4-benzyloxazolidin-2-on-3-yl)-carbonyl-4-methyl pentanoic acid and the potassium salt of monobenzyl malonic acid instead of the potassium salt of monoethyl malonic acid. Yield isolated after flash chromatography 69%.
  • the product is obtained by a procedure similar to that described in example 10 using (S)-3-(benzyloxycarbonyl)-4-methylpentanoic acid instead of (S)-3-((S)-4-benzyloxazolidin-2-on-3-yl)-carbonyl-4-methyl pentanoic acid and the potassium salt of monotert-butyl malonic acid instead of the potassium salt of monoethyl malonic acid. Yield isolated after flash chromatography 82%.
  • a four-necked flask is charged under nitrogen with anhydrous tetrahydrofuran (200 ml); it is cooled to 0° C. and a solution of titanium tetrachloride (18.40 g, 0.097 mol) in dichloromethane (24 ml) is added. A pale yellow suspension forms.
  • the resultant orange-coloured oil is purified by flash chromatography with gradient elution hexane-ethyl acetate 100:0 ⁇ 70:30 obtaining the desired product in the form of an approx. 1:3 mixture by HPLC of isomers of the double bond (yellow oil, 15.0 g, yield 46%).
  • the beta-ketoester obtained as described in example 17 (3.91 g, 5.86 mmol) is dissolved under nitrogen in acetic anhydride (46 ml), and 4-dimethylaminopyridine (358 mg, 2.93 mmol) and triethylamine (6.52 ml, 46.9 mmol) are added.
  • the reaction is monitored by HPLC; after 3 hours the reaction is completed and the mass is evaporated to residue. Then it is taken up in toluene and is washed with water to neutral pH. The residue is purified by flash chromatography with gradient elution hexane-ethyl acetate 100:0 ⁇ 70:30, obtaining the desired product (3.45 g, yield 83%) as colourless oil.
  • the beta-ketoester obtained as described in example 19A (3.71 g, 5.92 mmol) is dissolved under nitrogen in acetic anhydride (12 ml), and 4-dimethylaminopyridine (361 mg, 2.96 mmol) and triethylamine (6.60 ml, 47.35 mmol) are added.
  • the reaction is monitored by HPLC; after 3 hours the reaction is completed and the mass is evaporated to residue. Then it is taken up in toluene and is washed with a saturated water solution of sodium bicarbonate, water and finally brine.
  • the residue is purified by flash chromatography with gradient elution hexane-ethyl acetate 100:0 ⁇ 70:30, obtaining the desired product (3.16 g, yield 80%) as colourless oil.
  • a 500-mL four-necked flask equipped with thermometer, mechanical stirrer, and dropping funnel is charged under a nitrogen stream with the acid obtained in example 22 (21.0 g, 34.2 mmol); the acid is dissolved in 85 mL of acetone, it is cooled to ⁇ 10° C., triethylamine (3.80 g, 37.6 mmol) is added, it is stirred for 5 minutes and then a solution of ethyl chloroformate (4.1 g, 37.6 mmol) in acetone (28.3 mL) is added dropwise in about 30 minutes without exceeding a temperature of 0° C.
  • reaction mixture is poured into water (100 mL) and the phases are separated hot, the organic phase is washed with 1N HCl (100 mL) and concentrated to residue.
  • Triethylamine (1.01 g, 10.01 mmol, 1.15 eq.) is added under nitrogen to a 250-mL three-necked flask containing a solution of the acid obtained in example 22 (5.35 g, 8.70 mmol) in toluene (50 mL).
  • the solution is heated to 80° C. internal.
  • a solution of DPPA (2.51 g, 9.14 mmol, 1.05 eq.) in toluene (10 mL) is slowly added dropwise. After addition of the first drops of DPPA solution, evolution of nitrogen is observed. After addition, it is stirred at 80° C. for 1 h.
  • the reaction mixture is cooled to room temperature and water (100 mL) is added.
  • the phases are separated and the aqueous phase (which has pH ⁇ 7-8) is extracted with toluene (2 ⁇ 25 mL).
  • the combined organic phases are dried over anhydrous sodium sulphate, filtered and concentrated in a rotary evaporator. 6.92 g of raw product are obtained, as brown oil (theoretical 6.26 g, NMR reveals the presence of benzyl alcohol).
  • a 500-mL jacketed reactor is charged with a solution of the product obtained in example 23 (17.12 g, 23.8 mmol) in ethanol (342 mL) and 10% w/w HCl in water (85.6 mL). It is heated at 70° C. for 48 hours, monitoring the cyclization reaction by HPLC. On completion of reaction, it is cooled to 0° C., stirred for 1 hour and the product obtained is filtered, washing with cold ethanol (11.31 g, yield 83.5%).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
US13/701,440 2010-06-04 2011-06-03 Process for producing Aliskiren Expired - Fee Related US9346745B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
ITMI2010A001008A IT1400961B1 (it) 2010-06-04 2010-06-04 Processo per la produzione di aliskiren
ITMI2010A001008 2010-06-04
ITMI2010A1008 2010-06-04
ITMI2010A2271 2010-12-10
ITMI2010A002271A IT1402925B1 (it) 2010-12-10 2010-12-10 Processo per la produzione di aliskiren
ITMI2010A002271 2010-12-10
PCT/EP2011/059196 WO2011151442A2 (en) 2010-06-04 2011-06-03 Process for producing aliskiren

Publications (2)

Publication Number Publication Date
US20130071899A1 US20130071899A1 (en) 2013-03-21
US9346745B2 true US9346745B2 (en) 2016-05-24

Family

ID=44851511

Family Applications (1)

Application Number Title Priority Date Filing Date
US13/701,440 Expired - Fee Related US9346745B2 (en) 2010-06-04 2011-06-03 Process for producing Aliskiren

Country Status (7)

Country Link
US (1) US9346745B2 (de)
EP (1) EP2576500A2 (de)
AR (1) AR081836A1 (de)
CA (1) CA2801126A1 (de)
TW (1) TW201202178A (de)
UY (1) UY33425A (de)
WO (1) WO2011151442A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3006045T3 (en) * 2014-10-07 2017-07-17 Cyprumed Gmbh Pharmaceutical formulations for oral administration of peptide or protein drugs
CN114315749B (zh) * 2021-12-13 2024-04-26 湖南华腾医药有限公司 一种连续流微反应器合成阿利克仑中间体的方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559111A (en) 1994-04-18 1996-09-24 Ciba-Geigy Corporation δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides
WO2002002500A1 (en) 2000-07-03 2002-01-10 Speedel Pharma Ag Preparation of (r)-2-alkyl-3-phenylpropionic acids
WO2002008172A1 (en) 2000-07-25 2002-01-31 Speedel Pharma Ag Process for the preparation of substituted octanoyl amides
WO2006083924A1 (en) 2005-02-02 2006-08-10 Vitae Pharmaceuticals, Inc. 1-acylamino-2-hydroxy-3-amino-w-arylalkanes as renin inhibitors
US20080306311A1 (en) 2005-12-23 2008-12-11 Basf Se Method for Producing an Alpha-Chiral Chloromethyl Compound in a Pure Form
WO2009007461A1 (en) 2007-07-11 2009-01-15 Dsm Ip Assets B.V. Preparation of a saturated aldehyde
WO2009080773A1 (en) 2007-12-24 2009-07-02 Dsm Ip Assets B.V. Convergent synthesis of renin inhibitors and intermediates useful therein
WO2010010165A1 (en) 2008-07-23 2010-01-28 Dsm Ip Assets Bv Synthesis routes to 2(s),4(s),5(s),7(s)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoyl amides

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE9409707U1 (de) 1994-06-16 1994-09-15 Doppstadt, Werner, 42555 Velbert Walzenzerkleinerer
US6881868B2 (en) 2000-07-03 2005-04-19 Speedel Pharma Ag Process for the preparation of (R)-2-alkyl-3-phenyl-1-propanols

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559111A (en) 1994-04-18 1996-09-24 Ciba-Geigy Corporation δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides
WO2002002500A1 (en) 2000-07-03 2002-01-10 Speedel Pharma Ag Preparation of (r)-2-alkyl-3-phenylpropionic acids
WO2002008172A1 (en) 2000-07-25 2002-01-31 Speedel Pharma Ag Process for the preparation of substituted octanoyl amides
EP1303478A1 (de) 2000-07-25 2003-04-23 Speedel Pharma AG Verfahren zur herstellung von substituierten octanoyl-amiden
WO2006083924A1 (en) 2005-02-02 2006-08-10 Vitae Pharmaceuticals, Inc. 1-acylamino-2-hydroxy-3-amino-w-arylalkanes as renin inhibitors
US20080306311A1 (en) 2005-12-23 2008-12-11 Basf Se Method for Producing an Alpha-Chiral Chloromethyl Compound in a Pure Form
WO2009007461A1 (en) 2007-07-11 2009-01-15 Dsm Ip Assets B.V. Preparation of a saturated aldehyde
WO2009080773A1 (en) 2007-12-24 2009-07-02 Dsm Ip Assets B.V. Convergent synthesis of renin inhibitors and intermediates useful therein
WO2010010165A1 (en) 2008-07-23 2010-01-28 Dsm Ip Assets Bv Synthesis routes to 2(s),4(s),5(s),7(s)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoyl amides

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Boogers, J.A.F. et al., "A Mixed=Ligand Approach Enables the Asymmetric Hydrogenation of an a-Isopropylcinnamic Acid en Route to the Renin Inhibitor Aliskiren", Organic Process Research and Development, vol. 11, pp. 585-591, 2007.
Dong, H. et al., "Practical synthesis of an orally active renin inhibitor aliskiren", Tetrahedron Letters, vol. 46, pp. 6337-6340, 2005.
Jiang, B. et al., "Stereoselective synthesis of Certonardolsterol D3", Tetrahedron, vol. 64, pp. 9738-9744, 2008.
Rueger, H. et al., "A convergent synthesis approach towards CGP60536B, a non-peptide orally potent renin inhibitor, via an enantiomerically pure ketolactone intermediate", Tetrahedron Letters, vol. 41, pp. 10085-10089, 2000.
Yuan, Z. et al, "Graphical Synthetic Routes of Aliskiren", Chinese Journal of Pharaceuticals, 2009, vol. 40, No. 6., pp. 468-473.

Also Published As

Publication number Publication date
UY33425A (es) 2011-10-31
US20130071899A1 (en) 2013-03-21
TW201202178A (en) 2012-01-16
AR081836A1 (es) 2012-10-24
WO2011151442A3 (en) 2012-05-31
EP2576500A2 (de) 2013-04-10
WO2011151442A2 (en) 2011-12-08
CA2801126A1 (en) 2011-12-08

Similar Documents

Publication Publication Date Title
JP5579178B2 (ja) ２（ｓ），４（ｓ），５（ｓ），７（ｓ）−２，７−ジアルキル−４−ヒドロキシ−５−アミノ−８−アリール−オクタノイルアミドへの合成経路
EP2537825B1 (de) Verfahren zur herstellung von 1-amino-1-alkoxycarbonyl-2-vinylcyclopropan
JP4051082B2 (ja) 脂肪族ジニトリルのシアノカルボン酸への立体選択性生物変換
EP0674618B1 (de) Asymmetrisches herstellungsverfahren für florfenicol, thiamphenicol, chloramphenicol und oxazolin-zwischenprodukte
US20080311635A1 (en) Process for the preparation of (s)(+)-3-(aminomethyl)-5-methylhexanoic acid
JP2009046467A6 (ja) （ｓ）（＋）−３−（アミノメチル）−５−メチルヘキサン酸の調製方法
KR100294780B1 (ko) 반대배치를갖는폐물질로부터l-(-)-카르니틴의제조방법
US20130071899A1 (en) Process for Producing Aliskiren
JP4738416B2 (ja) Ｃａｎｄｉｄａａｎｔａｒｃｔｉｃａリパーゼを使用した光学分割による光学活性Ｎ−カルバメート保護化β−ラクタムを調製するためのプロセス
US20160122289A1 (en) Process for the preparation of an anticonvulsant agent pregabalin hydrochloride
US5714619A (en) Process for the preparation of (S)-β-hydroxy-γ-butyrolactone
ITMI20102271A1 (it) Processo per la produzione di aliskiren
ITMI20101008A1 (it) Processo per la produzione di aliskiren
JPS62275697A (ja) ラセミ体２−アミノ−１−アルカノ−ルの酵素による分割方法
JP5329973B2 (ja) リパーゼ触媒を用いるエナンチオ選択的アシル化とその後の硫酸による沈殿によって、ラセミ体の４−（１−アミノエチル）安息香酸メチルエステルから（ｒ）−および（ｓ）−４−（１−アンモニウムエチル）安息香酸メチルエステル硫酸塩を調製する方法
KR100341255B1 (ko) 4급 비대칭탄소를 함유하는 라세미체 알콜 화합물의 분할방법과 시스탄 유사체의 합성
JP2005298337A (ja) β−ヒドロキシアミノ酸誘導体の製造方法およびその中間体
DE102005062966A1 (de) Verfahren zur Herstellung von (R)- und (S)-4-(Ammoniumethyl)benzoesäuremethylester-sulfat
HK1161592B (en) Synthesis routes to 2(s),4(s),5(s),7(s)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoyl amides
JPH069549A (ja) 光学活性アジリジン−２−カルボン酸誘導体及びその製造方法
JPH10101640A (ja) 新規チオエステル
JPH08231477A (ja) 光学活性β−アミノエステル類の製造方法
DE102006001160A1 (de) Verfahren zur Herstellung von (R) und (S)-4-(1-Aminoethyl)benzoesäure-methylester
JPH10152459A (ja) １，３−ジアミノ−４−フェニル−２−ブタノール誘導体の製造方法、並びにその製造中間体及びその製造方法

Legal Events

Date Code Title Description
AS Assignment

Owner name: CHEMO IBERICA, S.A., SPAIN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TADDEI, MAURIZIO;RUSSO, ADELE;CINI, ELENA;AND OTHERS;SIGNING DATES FROM 20110623 TO 20110630;REEL/FRAME:029388/0377

STCF Information on status: patent grant

Free format text: PATENTED CASE

FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

LAPS Lapse for failure to pay maintenance fees

Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Expired due to failure to pay maintenance fee

Effective date: 20200524